Lupin to Present Phase I Data on LNP3693 at ESMO 2025 Congress

Lupin to Present Innovative LNP3693 Data at ESMO 2025

Lupin Limited is set to significantly impact the oncology landscape with their presentation on LNP3693, a novel STING agonist, during the upcoming ESMO 2025 Congress held in Berlin from October 17-21, 2025. This presentation follows their recently successful unveiling of LNP7457 at ASCO earlier in June 2025.

Presentation Details

The Phase I trial data will be part of a broader exploration into novel immunotherapeutic approaches in oncology. Titled "A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors and lymphoma," the session will occur on October 19, 2025, from 09:00 to 17:00 CEST. This presentation is particularly notable as it demonstrates the potential efficacy of LNP3693 in treating difficult-to-address solid tumors, showcasing the escalating need for innovative cancer therapies.

Insights into LNP3693

LNP3693 is an experimental injectable STING agonist designed to activate the innate immune system, a promising strategy in combating cancer. At the heart of the presentation will be qualitative insights into its safety profile, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in patients suffering from aggressive tumor types. These insights will offer a crucial advance in understanding how LNP3693 could shape future treatment paradigms in oncology.

Vinita Gupta, CEO of Lupin, expressed her enthusiasm about the upcoming presentation by stating, "This marks a significant milestone for us. Following the successful showcase of LNP7457, it is a privilege to present the findings from another Phase I trial, demonstrating our commitment to advancing cancer care and the recognition our research has garnered globally."

Importance of ESMO 2025

The ESMO Congress serves as a pivotal platform for sharing cutting-edge research and findings among healthcare professionals globally. All abstracts accepted for presentation at this esteemed congress will be published online on the ESMO website, providing accessibility to the latest scientific advancements. The final data presented will also be included in the Annals of Oncology, ensuring a wide dissemination of the findings post-convention.

For those interested in attending or learning more about the ESMO 2025 Congress, additional information is available at ESMO's official website.

About Lupin Limited

Founded in Mumbai, India, Lupin Limited is a key player in the global pharmaceutical industry, with a product portfolio that spans over 100 countries. The company specializes in generic and branded formulations, complex generics, biopharmaceuticals, and active pharmaceutical ingredients (APIs). With a robust team of over 24,000 employees and a strong presence in significant therapeutic areas, Lupin is committed to enhancing patient care and advancing global health outcomes through innovative research and development.

For more information on Lupin, explore their official website or follow them on LinkedIn.